Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS ...
The U.S. Food and Drug Administration (FDA) has granted rare pediatric drug designation for iopofosine-131 in inoperable relapsed or refractory pediatric high-grade glioma (pHGG), according to a news ...
Iopofosine I 131 is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a ...
Studies show patients with chronic kidney disease (CKD) and COVID-19 are at increased risk for an intensive care unit stay and early death. Anemia is an extra risk factor.
Agios Pharmaceuticals (($AGIO)) announced an update on their ongoing clinical study. Agios Pharmaceuticals is conducting a study titled ‘A Phase ...
Akebia Therapeutics (($AKBA)) announced an update on their ongoing clinical study. Akebia Therapeutics recently updated its clinical study titled ...
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority ...
Novartis said it is acquiring Avidity Biosciences for approximately $12 billion, the companies said Sunday, in a deal designed to bolster the buyer’s neuroscience pipeline with three late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback